MDS Colombia SAS
Welcome,         Profile    Billing    Logout  
 16 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Blazy, Dominique
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
KEYNOTE-051, NCT02332668 / 2014-002950-38: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/)

Checkmark Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Dec 2019 - Dec 2019: Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Recruiting
1/2
370
Europe, US, RoW
Pembrolizumab, MK-3475
Merck Sharp & Dohme LLC
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
10/27
10/27
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27
Teper, Gally
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
KEYNOTE-051, NCT02332668 / 2014-002950-38: A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/)

Checkmark Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Dec 2019 - Dec 2019: Interim analysis from KEYNOTE-051 trial in adv. melanoma or PDL1+ve, adv. r/r solid tumour or lymphoma
Recruiting
1/2
370
Europe, US, RoW
Pembrolizumab, MK-3475
Merck Sharp & Dohme LLC
Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
10/27
10/27
Carvajal, Francesca
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
Fijolek, Artur
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
KEYNOTE-365, NCT02861573 / 2016-002312-41: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/)

Checkmark 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Sep 2022 - Sep 2022: 2-year follow-up data from KEYNOTE-365 trial in chemotherapy-naïve mCRPC at ESMO 2022
Recruiting
1/2
1200
Europe, Canada, US, RoW
Pembrolizumab 200 mg, KEYTRUDA®, MK-3475, Olaparib 400 mg, LYNPARZA®, MK-7339, Docetaxel 75 mg/m^2, TAXOTERE®, Prednisone 5 mg, Enzalutamide 160 mg, XTANDI®, Dexamethasone 8 mg, Olaparib 300 mg, Abiraterone acetate 1000 mg, ZYTIGA®, Lenvatinib, LENVIMA®, MK-7902, Pembrolizumab/Vibostolimab coformulation, MK-7684A, Carboplatin, PARAPLATIN®, Etoposide, TOPOSAR™, Belzutifan 120mg, WELIREG™
Merck Sharp & Dohme LLC
Metastatic Castration-Resistant Prostate Cancer
10/27
10/27

Download Options